MCID: KDN018
MIFTS: 73

Kidney Disease

Categories: Blood diseases, Bone diseases, Nephrological diseases

Aliases & Classifications for Kidney Disease

MalaCards integrated aliases for Kidney Disease:

Name: Kidney Disease 12 6 15 17
Renal Failure 75 55 40 33
Nephropathy 12 75 29 6
Kidney Diseases 43 44 72
Kidney Failure 43 17 72
Abnormality of the Kidney 29 6
Renal Failure Adverse Event 72
Abnormal Renal Function 72
Kidney Dysfunction 55
Renal Anomaly 55
Renal Disease 55
Nephropathies 15

Classifications:



External Ids:

Disease Ontology 12 DOID:557
MeSH 44 D007674
NCIt 50 C3149 C34843
SNOMED-CT 68 90708001
UMLS 72 C0022658 C0035078 C0151746 more

Summaries for Kidney Disease

MedlinePlus : 43 Healthy kidneys clean your blood by removing excess fluid, minerals, and wastes. They also make hormones that keep your bones strong and your blood healthy. But if the kidneys are damaged, they don't work properly. Harmful wastes can build up in your body. Your blood pressure may rise. Your body may retain excess fluid and not make enough red blood cells. This is called kidney failure. If your kidneys fail, you need treatment to replace the work they normally do. The treatment options are dialysis or a kidney transplant. Each treatment has benefits and drawbacks. No matter which treatment you choose, you'll need to make some changes in your life, including how you eat and plan your activities. But with the help of health care providers, family, and friends, most people with kidney failure can lead full and active lives. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Kidney Disease, also known as renal failure, is related to polycystic kidney disease 1 with or without polycystic liver disease and polycystic kidney disease, and has symptoms including polyuria An important gene associated with Kidney Disease is COL4A5 (Collagen Type IV Alpha 5 Chain), and among its related pathways/superpathways is Organelle biogenesis and maintenance. The drugs Nicotinamide and Zaleplon have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and heart, and related phenotypes are cellular and cardiovascular system

Disease Ontology : 12 A urinary system disease that is located in the kidney.

Wikipedia : 75 Kidney disease, or renal disease, also known as nephropathy, is damage to or disease of a kidney.... more...

Related Diseases for Kidney Disease

Diseases in the Kidney Disease family:

Acute Kidney Failure Renal Infectious Disease
Chronic Kidney Disease

Diseases related to Kidney Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 3071)
# Related Disease Score Top Affiliating Genes
1 polycystic kidney disease 1 with or without polycystic liver disease 35.9 PKHD1 PKD2L1 PKD2 PKD1 IFT88
2 polycystic kidney disease 35.9 PKHD1 PKD2L1 PKD2 PKD1 IFT88 ACE
3 autosomal dominant polycystic kidney disease 35.7 PKHD1 PKD2L1 PKD2 PKD1 CST3 ALB
4 polycystic kidney disease 4 with or without polycystic liver disease 35.7 TMEM67 PKHD1 PKD2 PKD1 IFT88
5 polycystic kidney disease 2 with or without polycystic liver disease 35.7 PKHD1 PKD2L1 PKD2 PKD1 IFT88
6 cystic kidney disease 35.4 UMOD TMEM67 PKHD1 PKD2L1 PKD2 PKD1
7 end stage renal failure 34.8 UMOD PKD1 EPO CST3 COL4A5 ALB
8 nephronophthisis 34.4 UMOD TMEM67 PKHD1 PKD2 PKD1 CEP290
9 polycystic liver disease 33.7 PKHD1 PKD2 PKD1 ALB
10 glomerulonephritis 33.6 COL4A5 COL4A4 ALB
11 calciphylaxis 33.5 EPO CASR ALB
12 polycystic liver disease 1 with or without kidney cysts 33.5 UMOD PKHD1 PKD2 PKD1
13 caroli disease 33.5 PKHD1 PKD1
14 orofaciodigital syndrome i 33.4 IFT88 CEP290
15 focal segmental glomerulosclerosis 33.4 COL4A5 COL4A4 ALB ACE
16 congenital hepatic fibrosis 33.4 TMEM67 PKHD1 PKD1
17 membranous nephropathy 33.3 B2M ALB ACE
18 multicystic dysplastic kidney 32.7 PKD2 PKD1
19 uremia 32.5 EPO CASR B2M ALB
20 liver disease 32.4 PKHD1 PKD2 PKD1 ALB
21 pyelonephritis 32.3 UMOD ALB ACE
22 acute kidney failure 32.3 CST3 B2M ALB
23 interstitial nephritis 32.3 UMOD ALB ACE
24 nephronophthisis 19 32.2 UMOD TMEM67
25 hypertension, essential 32.2 PKD2 PKD1 CST3 COL4A5 ALB ACE
26 joubert syndrome 6 32.1 TMEM67 CEP290
27 renal hypertension 32.0 EPO ALB ACE
28 meckel syndrome, type 1 32.0 TMEM67 IFT88 CEP290
29 urinary tract obstruction 31.9 UMOD B2M ALB
30 acute kidney tubular necrosis 31.9 UMOD CST3 B2M ALB
31 oligohydramnios 31.8 TMEM67 PKHD1 ACE
32 peritonitis 31.7 TMEM67 B2M ALB
33 nephrocalcinosis 31.5 UMOD CASR ALB
34 hepatorenal syndrome 31.5 CST3 ALB ACE
35 meckel syndrome, type 3 31.3 TMEM67 CEP290
36 al amyloidosis 31.2 CST3 B2M
37 anti-basement membrane glomerulonephritis 31.1 COL4A5 COL4A4
38 acquired immunodeficiency syndrome 31.1 NEAT1 EPO B2M ALB
39 secondary hyperparathyroidism of renal origin 31.0 EPO CASR ALB
40 osteitis fibrosa 31.0 CASR B2M
41 uremic neuropathy 31.0 EPO B2M
42 orthostatic proteinuria 30.8 B2M ALB ACE
43 hypertensive encephalopathy 30.7 EPO ACE
44 renal artery disease 30.6 EPO ACE
45 hematuria, benign familial 30.4 COL4A5 COL4A4
46 diffuse glomerulonephritis 30.4 B2M ALB
47 encephalocele 30.4 TMEM67 CEP290
48 non-secretory myeloma 29.8 B2M ALB
49 chronic kidney disease 12.9
50 medullary cystic kidney disease 1 12.8

Comorbidity relations with Kidney Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 51)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Myocardial Infarction
Alzheimer Disease Aortic Valve Disease 1
Bladder Neck Obstruction Bronchitis
Bronchopneumonia Cardiac Arrest
Cardiogenic Shock Decubitus Ulcer
Deficiency Anemia Diabetic Polyneuropathy
Encephalopathy Esophagitis
Familial Atrial Fibrillation First-Degree Atrioventricular Block
Generalized Atherosclerosis Gout
Heart Disease Hydronephrosis
Hypertension, Essential Hypoglycemia
Hypoglycemic Coma Hypothyroidism
Intermediate Coronary Syndrome Intestinal Obstruction
Iron Deficiency Anemia Malignant Essential Hypertension
Microvascular Complications of Diabetes 1 Mitral Valve Disease
Nephrosclerosis Paralytic Ileus
Peripheral Vascular Disease Polycystic Kidney Disease
Prostate Cancer Prostatic Hypertrophy
Protein-Energy Malnutrition Pulmonary Hypertension, Primary, 1
Pyelonephritis Renal Artery Atheroma
Renal Artery Disease Respiratory Failure
Schizophreniform Disorder Sinoatrial Node Disease
Swallowing Disorders Third-Degree Atrioventricular Block
Transient Cerebral Ischemia Tricuspid Valve Disease

Graphical network of the top 20 diseases related to Kidney Disease:



Diseases related to Kidney Disease

Symptoms & Phenotypes for Kidney Disease

UMLS symptoms related to Kidney Disease:


polyuria

MGI Mouse Phenotypes related to Kidney Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.23 ALB B2M CASR CEP290 EPO IFT88
2 cardiovascular system MP:0005385 10.22 ACE B2M CEP290 COL4A5 CST3 EPO
3 growth/size/body region MP:0005378 10.14 ACE B2M CASR CEP290 COL4A4 IFT88
4 homeostasis/metabolism MP:0005376 10.13 ACE ALB B2M CASR CEP290 COL4A4
5 digestive/alimentary MP:0005381 10.09 ALB B2M CASR COL4A4 IFT88 PKD1
6 hematopoietic system MP:0005397 10.07 ACE B2M CASR CEP290 COL4A5 EPO
7 immune system MP:0005387 10.03 ACE B2M CASR CEP290 COL4A4 COL4A5
8 liver/biliary system MP:0005370 9.85 ACE ALB B2M CEP290 EPO IFT88
9 mortality/aging MP:0010768 9.8 ACE ALB B2M CASR CEP290 COL4A4
10 renal/urinary system MP:0005367 9.4 ACE ALB CASR CEP290 COL4A4 COL4A5

Drugs & Therapeutics for Kidney Disease

Drugs for Kidney Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1263)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
2
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
3
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
4
Pancrelipase Approved, Investigational Phase 4 53608-75-6
5
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
6
Capsaicin Approved Phase 4 404-86-4 1548943
7
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
8
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
9
Atenolol Approved Phase 4 29122-68-7 2249
10
Scopolamine Approved, Investigational Phase 4 6533-68-2, 51-34-3 5184
11
Nefopam Approved, Investigational Phase 4 13669-70-0
12
Ticlopidine Approved Phase 4 55142-85-3 5472
13
Glyburide Approved Phase 4 10238-21-8 3488
14
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 130881 158781
15
Indapamide Approved Phase 4 26807-65-8 3702
16
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
17
Colchicine Approved Phase 4 64-86-8 6167 2833
18
Sevelamer Approved Phase 4 52757-95-6
19
Daptomycin Approved, Investigational Phase 4 103060-53-3 16129629
20
Nisoldipine Approved Phase 4 63675-72-9 4499
21
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
22
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
23
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
24
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
25
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
26
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
27
Telavancin Approved Phase 4 372151-71-8
28
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
29
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
30
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
31
Glucagon Approved Phase 4 16941-32-5
32
Liraglutide Approved Phase 4 204656-20-2 44147092
33
Rifaximin Approved, Investigational Phase 4 80621-81-4 46783403 6436173
34
Insulin glulisine Approved Phase 4 207748-29-6
35
Dolutegravir Approved Phase 4 1051375-16-6 54726191
36
Probucol Approved, Investigational Phase 4 23288-49-5 4912
37
Zidovudine Approved Phase 4 30516-87-1 35370
38
Donepezil Approved Phase 4 120014-06-4 3152
39
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
40
Doxazosin Approved Phase 4 74191-85-8 3157
41
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
42
Calcium acetate Approved, Investigational Phase 4 62-54-4
43
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
44
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
45
Azathioprine Approved Phase 4 446-86-6 2265
46
Fosinopril Approved Phase 4 98048-97-6 55891
47
Rilonacept Approved, Investigational Phase 4 501081-76-1 104924
48
Deflazacort Approved, Investigational Phase 4 14484-47-0
49
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
50
Lixisenatide Approved Phase 4 320367-13-3

Interventional clinical trials:

(show top 50) (show all 7528)
# Name Status NCT ID Phase Drugs
1 Effect of Hydration With Sodium Bicarbonate for Long-Term Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing an Emergent Coronary Procedure Unknown status NCT00716001 Phase 4 N-acetylcysteine
2 The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients Unknown status NCT00247507 Phase 4 acetylcysteine
3 A Prospective Randomized, Double-Blind Parallel Group Trial To Assess The Efficacy And Safety Of Intravenous Dextrose 5% Solution Compare With Normal Saline (Standard Care) In Rinsing During Haemodialysis In Subjects With End Stage Renal Failure (ESRF) With Respect To Systolic Blood Pressure Control Over 3 Months Period. Unknown status NCT02590081 Phase 4 Dextrose 5%;normal saline
4 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes Unknown status NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
5 Phase 4 Study of Alprostadil Prevent Contrast Induced Nephropathy in Patients Receiving a Cardiac Catheterization Unknown status NCT01722513 Phase 4 Alprostadil ﹠control
6 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
7 Phase 4 Study of Medical Therapy Versus Medical Therapy Plus Renal Artery Stenting in Preventing the Progression of Renal Failure in Atherosclerotic Renovascular Disease Unknown status NCT01023373 Phase 4 Medical treatment
8 Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy. Unknown status NCT00870402 Phase 4 Spironolactone;Placebo
9 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
10 A comParison on Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Study Among SeVerE Chronic Kidney Disease/ End-Stage-Renal-Disease Patients With Recent Acute Coronary Syndrome. Unknown status NCT02459288 Phase 4 Clopidogrel first;Ticagrelor first
11 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease: a Randomized Clinical Trial Unknown status NCT01155128 Phase 4
12 Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease Unknown status NCT00852787 Phase 4 Digoxin immune fab;Placebo
13 Renoprotection by Combining Pentoxifylline and Angiotensin Blockade in Chronic Kidney Disease Unknown status NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
14 NAC in Preventing CIN in CRF Patients Who Need Enhanced CT Scan in ED Unknown status NCT00501475 Phase 4 NAC Bicarbonate
15 Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
16 A Prospective, Multi-center, Randomized, Open-label, Parallel-arm Controlled Study of Treating Type 2 Diabetic Nephropathy (Stage II-IV) With Alfacalcidol and Irbesartan Unknown status NCT03147677 Phase 4 Alfacalcidol;Irbesartan
17 The Metabolic and Anti-Inflammatory Effects of Combined Ezetimibe and Simvastin Therapy, as Compared to Simvastatin Alone, in Patients With Chronic Proteinuric Nephropathy Unknown status NCT00861731 Phase 4 simvastatin;EZE/simvastatin;EZE/simvastatin
18 Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease Unknown status NCT02885857 Phase 4 Shenyan Kangfu Tablet
19 The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Unknown status NCT01157260 Phase 4 Kremezin
20 Open Randomized Phase IV Study on Intravenous Iron in Anemic Patients With Chronic Kidney Disease Unknown status NCT00204256 Phase 4 Iron sucrose
21 Phase 4 Study of Sarpogrelate That Prevent Contrast-induced Nephropathy Unknown status NCT01165567 Phase 4 sarpogrelate
22 Preventive Strategies of REnal Insufficiency in Patients With Diabetes Undergoing InterVENTion or Arteriography(PREVENT Trial) Unknown status NCT00950079 Phase 4 Sodium bicarbonate;saline
23 Effect of Intravenous and Oral Therapy With Sulodexide on Albuminuria in Type 2 Diabetic Patients Unknown status NCT01316068 Phase 4 intravenous use of sulodexide followed by oral use;use of sulodexide orally only
24 Preventing Contrast Induced Nephropathy After Transcatheter Aortic Valve Replacement Unknown status NCT03121053 Phase 4 sodium bicarbonate;hypotone saline
25 Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial Unknown status NCT02231125 Phase 4 Losartan;Abelmoschus manihot
26 Phase IV, Effect of Rennin-Angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria--- A Randomized Controlled Trial Unknown status NCT01500590 Phase 4 Renin-angiotensin system blockers;non-renin angiotensin system blockers
27 Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease: An Interventional and Methodological Study Unknown status NCT00235287 Phase 4 Candesartan and enalapril;candesartan and enalapril;candesartan and enalapril;candesartan and enalapril
28 Comparison of Efficacy and Safety Between Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension: a Randomized Controlled Trial Unknown status NCT02646397 Phase 4 Fosinopril;Benidipine;Hydrochlorothiazide
29 Preventive Effect of the PRetreatment With pItavastatiN on Contrast-Induced Nephropathy in Patients With RenaL Dysfunction UndErgoing Coronary Angiography/Intervention (PRINCIPLE-II Study) Unknown status NCT01871792 Phase 4 Pitavastatin;Placebo
30 Evaluation of Cholecalciferol Supplementation in Chronic Kidney Disease Patients With Restless Leg Syndrome Unknown status NCT03063190 Phase 4 Vitamin D;Placebo Oral Tablet
31 The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
32 Simvastatin Effect on Endothelium Dependent Venodilation in Chronic Renal Failure Patients Treated by Peritoneal Dialysis Unknown status NCT00291863 Phase 4 Simvastatin
33 Calcineurin Inhibitor Minimisation in Renal Transplant Recipients With Stable Allograft Function: A Prospective Randomised Controlled Trial Unknown status NCT00541814 Phase 4 Cyclosporine
34 Providing Intravenous Paricalcitol Treatment to the Sick and Poor Chronic Hemodialysis Patients With Severe Secondary Hyperparathyroidism Resistant to Existing Vitamin D Analogs Unknown status NCT03023748 Phase 4 Intravenous Paricalcitol
35 Effect of Ursodeoxycholic Acid on Peritoneal Function in Patients on Peritoneal Dialysis Unknown status NCT02338635 Phase 4 Ursodeoxycholic Acid
36 A Randomized Prospective Trial of N-acetyl Cystein in Patients With Peritoneal Dialysis Unknown status NCT01111422 Phase 4 N-acetylcysteine
37 Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy: a 24- Week Study Unknown status NCT02690883 Phase 4 Exenatide;Lispro
38 A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
39 Comparison Between ARB and ARB Plus CCB on Incidence of Renal and Cardiovascular Events in Hypertensive ADPKD Patients Unknown status NCT00541853 Phase 4 Candesartan;Candesartan and Cilnidipine;Candesartan plus non-CCB agents
40 N-Acetylcysteine to Prevent Contrast-Induced Nephropathy in Acute Coronary Syndromes Unknown status NCT00939913 Phase 4 intravenous NAC;Placebo
41 The Immunogenicity and Safety of the Seasonal Influenza Vaccine, Formulation 2013-2014, in Chronic Kidney Disease Patients Not on Dialysis Unknown status NCT02105519 Phase 4
42 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
43 Nephropathy in Type 2 Diabetes: Effects of an Intensive Multifactorial Intervention Trial on Cardio-renal Events. Unknown status NCT00535925 Phase 4 current therapy;irbesartan;ramipril;hydrochlorothiazide;furosemide;amlodipine;atenolol;doxazosin;clonidine;insulin;simvastatin;fibrate;erythropoietin;aspirin
44 Interstitial Fibrosis in Protocol Biopsies of Renal Allografts: A Prospective, Randomised Trial of Sirolimus Versus Cyclosporine.(Fibrasic) Unknown status NCT00493194 Phase 4 sirolimus;cyclosporine;daclizumab
45 A Pilot Study to Treat Patients With Chronic HCV Genotype 1 and ESRD Receiving Hemodialysis and Naïve to Prior HCV Therapy With Peginterferon Alfa-2b, the Maximally Tolerated Ribavirin Dose and Boceprevir Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
46 Renal Toxicity of Iodixanol and Iopromide in Patients With Renal Dysfunction—a Multicentre, Single Blind, Randomized Controlled, Prospective Trial Unknown status NCT01580046 Phase 4 iodixanol;iopromide
47 Safety of Add on Aliskiren to ACEI and ARB Treatment in Type 2 Diabetes With Nephropathy Unknown status NCT00949351 Phase 4 Aliskiren 300mg/d
48 Inspiratory Muscle Training in Patients With End Stage Renal Failure: a Randomized Controlled Trial Unknown status NCT01347775 Phase 4
49 Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease:a Multicentre Open Study Unknown status NCT02231138 Phase 4 Abelmoschus manihot (AM)
50 Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease Unknown status NCT02299310 Phase 4 Valsartan;Perindopril

Search NIH Clinical Center for Kidney Disease

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Albumin Human, USP
ALBUMIN,HUMAN INJ
Dopamine
Dopamine Hydrochloride
Iothalamic acid

Cochrane evidence based reviews: kidney diseases

Genetic Tests for Kidney Disease

Genetic tests related to Kidney Disease:

# Genetic test Affiliating Genes
1 Nephropathy 29
2 Abnormality of the Kidney 29

Anatomical Context for Kidney Disease

MalaCards organs/tissues related to Kidney Disease:

41
Kidney, Bone, Heart, Liver, Endothelial, Testes, Neutrophil

The Foundational Model of Anatomy Ontology organs/tissues related to Kidney Disease:

19
Kidney

Publications for Kidney Disease

Articles related to Kidney Disease:

(show top 50) (show all 62374)
# Title Authors PMID Year
1
Updated Clinical Practice Guideline on Use of Gadolinium-Based Contrast Agents in Kidney Disease Issued by the Canadian Association of Radiologists. 38 17
31255393 2019
2
Effects of febuxostat on renal function in patients with chronic kidney disease: A systematic review and meta-analysis. 38 17
31335677 2019
3
Exertional rhabdomyolysis in a 21-year-old healthy man resulting from lower extremity training: A case report. 17
31305403 2019
4
Rhabdomyolysis-induced acute kidney injury in a patient with undifferentiated connective tissue disease: A case report and literature review rhabdomyolysis-induced AKI in a patient with UCTD. 17
31348259 2019
5
Clinicopathologic correlations of renal biopsy findings from northeast China: A 10-year retrospective study. 17
31169695 2019
6
Impact of renal dysfunction on surgical outcomes in patients with aortic dissection. 17
31096441 2019
7
miR-200a Prevents renal fibrogenesis through repression of TGF-β2 expression. 88
20952520 2011
8
Tumor necrosis factor (TNF-alpha) and C-reactive protein (CRP) are positively associated with the risk of chronic kidney disease in patients with type 2 diabetes. 9 38
20499416 2010
9
Evidence for a role of uromodulin in chronic kidney disease progression. 9 38
20075439 2010
10
Increment and impairment of adiponectin in renal failure. 9 38
20035033 2010
11
Benefits of catalase overexpression in renal proximal tubular cells. 9 38
20508664 2010
12
An aid to the diagnosis of genetic disorders underlying adult-onset renal failure: a literature review. 9 38
20497759 2010
13
Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy. 9 38
20061322 2010
14
Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. 9 38
20200094 2010
15
An integrative view on the role of TGF-beta in the progressive tubular deletion associated with chronic kidney disease. 9 38
20336053 2010
16
Performance evaluation of a particle-enhanced turbidimetric cystatin C assay using the Abbott Aeroset analyser and assessment of cystatin C-based equations for estimating glomerular filtration rate in chronic kidney disease. 9 38
20037185 2010
17
Serum creatinine, cystatin C, and beta-trace protein in diagnostic staging and predicting progression of primary nondiabetic chronic kidney disease. 9 38
20224047 2010
18
Is collapsing C1q nephropathy another MYH9-associated kidney disease? A case report. 9 38
20116156 2010
19
Albuminuria, impaired kidney function and cardiovascular outcomes or mortality in the elderly. 9 38
20008829 2010
20
Uromodulin is expressed in renal primary cilia and UMOD mutations result in decreased ciliary uromodulin expression. 9 38
20172860 2010
21
Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease. 9 38
20470305 2010
22
Circulating levels of osteopontin are closely related to glomerular filtration rate and cardiovascular risk markers in patients with chronic kidney disease. 9 38
20486990 2010
23
Predicting potential survival benefit of renal transplantation in patients with chronic kidney disease. 9 38
20351122 2010
24
The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. 9 38
20157196 2010
25
Is Fibroblast Growth Factor-23 a novel marker for phosphate burden in chronic kidney disease with prognostic implications? 9 38
20503017 2010
26
Molecular diagnostics for autosomal dominant polycystic kidney disease. 9 38
20177400 2010
27
The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. 9 38
20133489 2010
28
Aldose reductase inhibitors and diabetic kidney disease. 9 38
20336588 2010
29
Terlipressin therapy for renal failure in cirrhosis. 9 38
19952764 2010
30
Antagonists of bone morphogenetic proteins in kidney disease. 9 38
20178045 2010
31
Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels. 9 38
19948877 2010
32
Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. 9 38
20150538 2010
33
HMG CoA reductase inhibition and endothelial function in children with chronic kidney disease (CKD)--a pilot study. 9 38
20050832 2010
34
Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. 9 38
20016471 2010
35
Diagnostic accuracy of various glomerular filtration rates estimating equations in patients with chronic kidney disease and diabetes. 9 38
20368098 2010
36
Erythropoietin response to anemia and its association with autonomic neuropathy in type 2 diabetic patients without advanced renal failure. 9 38
19303331 2010
37
Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease. 9 38
20133492 2010
38
Does the downregulation of the FGF23 signaling pathway in hyperplastic parathyroid glands contribute to refractory secondary hyperparathyroidism in CKD patients? 9 38
20150940 2010
39
Genetics of focal segmental glomerulosclerosis and human immunodeficiency virus-associated collapsing glomerulopathy: the role of MYH9 genetic variation. 9 38
20347641 2010
40
The angiotensin II type 2 receptor in renal disease. 9 38
19861345 2010
41
A prospective study of fibroblast growth factor-23 in children with chronic kidney disease. 9 38
19929273 2010
42
FGF23-parathyroid interaction: implications in chronic kidney disease. 9 38
20010546 2010
43
Alterations of retinol-binding protein 4 species in patients with different stages of chronic kidney disease and their relation to lipid parameters. 9 38
20097162 2010
44
Genetic variation at selected SNPs in the leptin gene and association of alleles with markers of kidney disease in a Xhosa population of South Africa. 9 38
20140086 2010
45
PKHD1 sequence variations in 78 children and adults with autosomal recessive polycystic kidney disease and congenital hepatic fibrosis. 9 38
19914852 2010
46
CRP polymorphisms and progression of chronic kidney disease in African Americans. 9 38
19965533 2010
47
Is cystatin C a useful marker in the detection of diabetic kidney disease? 9 38
19887833 2010
48
Plasma adiponectin levels in chronic kidney disease patients: relation with molecular inflammatory profile and metabolic status. 9 38
19359150 2010
49
[Chronic kidney disease and the aldosterone/mineralocorticoid receptor system]. 9 38
20415233 2010
50
Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study. 9 38
20309434 2010

Variations for Kidney Disease

ClinVar genetic disease variations for Kidney Disease:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 CEP290 NM_025114.3(CEP290): c.3104-2A> G single nucleotide variant Pathogenic rs773386777 12:88487754-88487754 12:88093977-88093977
2 COL4A5 NM_033380.2(COL4A5): c.1424-2_1430delAGGTGACAA deletion Pathogenic rs1556411578 X:107838737-107838745 X:108595507-108595515
3 CEP290 NM_025114.3(CEP290): c.5493delA (p.Ala1832Profs) deletion Pathogenic rs386834158 12:88471567-88471567 12:88077790-88077790
4 TMEM67 NM_153704.5(TMEM67): c.1843T> C (p.Cys615Arg) single nucleotide variant Pathogenic/Likely pathogenic rs201893408 8:94808198-94808198 8:93795970-93795970
5 TMEM67 NM_153704.5(TMEM67): c.1321C> T (p.Arg441Cys) single nucleotide variant Pathogenic/Likely pathogenic rs752362727 8:94798483-94798483 8:93786255-93786255
6 PKD1 NM_001009944.3(PKD1): c.3785A> G (p.His1262Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs1057518976 16:2161383-2161383 16:2111382-2111382
7 PAX9 ; SLC25A21 deletion Uncertain significance 14:37145358-37162210 :0-0

Copy number variations for Kidney Disease from CNVD:

7 (show all 21)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 37196 1 8700000 16000000 Deletion renal disease
2 76925 13 38159172 38359267 Copy number FREM2 renal disease
3 95843 15 81011700 83540700 Deletion renal disease
4 97939 16 14780000 16770000 Deletion renal disease
5 110304 17 31836750 33582750 Microdeletion BC1D3 renal disease
6 110305 17 31836750 33582750 Microdeletion CCL3L1 renal disease
7 110306 17 31836750 33582750 Microdeletion CCL4L1 renal disease
8 110307 17 31836750 33582750 Microdeletion TCF2 renal disease
9 110539 17 33120546 33179209 Copy number HNF1B renal disease
10 110540 17 33120546 33179209 Copy number TCF2 renal disease
11 110544 17 33120546 33179209 Deletion TCF2 renal disease
12 115163 17 55061600 55218400 Duplication renal disease
13 127179 19 28500000 63811651 Microdeletion renal disease
14 127247 19 30200000 37100000 Deletion renal disease
15 128207 19 40300000 43000000 Deletion renal disease
16 160230 22 11800000 24300000 Deletion renal disease
17 189838 4 79197747 79684447 Copy number FRAS1 renal disease
18 191442 5 1 12100000 Duplication renal disease
19 222025 7 148600000 158550000 Deletion renal disease
20 264973 X 71600000 71800000 Duplication renal disease
21 22040 1 16450000 16950000 Duplication renal disease

Expression for Kidney Disease

Search GEO for disease gene expression data for Kidney Disease.

Pathways for Kidney Disease

Pathways related to Kidney Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.75 TMEM67 PKD2 PKD1 IFT88 CEP290

GO Terms for Kidney Disease

Cellular components related to Kidney Disease according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.92 PKD2L1 PKD1 EPO CASR B2M
2 endoplasmic reticulum lumen GO:0005788 9.8 CST3 COL4A5 COL4A4 B2M ALB
3 basolateral plasma membrane GO:0016323 9.76 UMOD PKD2 PKD1 CASR
4 cell projection GO:0042995 9.76 UMOD TMEM67 PKHD1 PKD2L1 PKD2 PKD1
5 ciliary basal body GO:0036064 9.67 PKHD1 PKD2 IFT88 CEP290
6 MKS complex GO:0036038 9.51 TMEM67 CEP290
7 non-motile cilium GO:0097730 9.5 PKD2L1 PKD2 IFT88
8 collagen type IV trimer GO:0005587 9.43 COL4A5 COL4A4
9 ciliary membrane GO:0060170 9.35 UMOD TMEM67 PKD2L1 PKD2 PKD1
10 polycystin complex GO:0002133 9.26 PKD2 PKD1
11 cilium GO:0005929 9.23 UMOD TMEM67 PKHD1 PKD2L1 PKD2 PKD1
12 extracellular exosome GO:0070062 10.14 UMOD PKHD1 PKD2 PKD1 CST3 B2M
13 extracellular region GO:0005576 10.13 UMOD EPO CST3 COL4A5 COL4A4 CEP290
14 extracellular space GO:0005615 10.1 MIR141 EPO CST3 COL4A5 COL4A4 B2M

Biological processes related to Kidney Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cilium assembly GO:0060271 9.67 TMEM67 PKHD1 IFT88 CEP290
2 cellular calcium ion homeostasis GO:0006874 9.65 PKHD1 PKD2 CASR
3 positive regulation of protein binding GO:0032092 9.58 PKD1 B2M ACE
4 placenta blood vessel development GO:0060674 9.46 PKD2 PKD1
5 cytoplasmic sequestering of transcription factor GO:0042994 9.43 PKD2 PKD1
6 kidney development GO:0001822 9.35 PKHD1 PKD2 PKD1 IFT88 ACE
7 detection of mechanical stimulus GO:0050982 9.33 PKD2L1 PKD2 PKD1
8 mesonephric tubule development GO:0072164 9.32 PKD2 PKD1
9 mesonephric duct development GO:0072177 9.26 PKD2 PKD1
10 metanephric ascending thin limb development GO:0072218 8.8 UMOD PKD2 PKD1

Molecular functions related to Kidney Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.8 PKD2L1 PKD2 CST3 CEP290 B2M ALB
2 ion channel binding GO:0044325 9.54 PKD2 PKD1 CASR
3 alpha-actinin binding GO:0051393 9.26 PKD2L1